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Abstract
Accurately identifying close or positive margins in real-time permits re-excision during surgical procedures.
Intraoperative assessment of margins via gross examination and frozen section is a widely used tool to assist
the surgeon in achieving complete resection. While this methodology permits diagnosis of freshly resected tis-
sue, the process is fraught with misinterpretation and sampling errors. During fluorescence-guided surgery, an
exogenous fluorescent agent specific for the target disease is imaged in order to navigate the surgical exci-
sion. As this technique quickly advances into the clinic, we hypothesize that the disease-specific fluorescence
inherently contained within the resected tissues can be used to guide histopathological assessment. To evalu-
ate the feasibility of fluorescence-guided pathology, we evaluated head and neck squamous cell carcinoma
tumour specimens and margins resected from animals and patients after systemic injection of cetuximab-
IRDye800CW. In a preclinical model of luciferase-positive tumour resection using bioluminescence as the gold
standard, fluorescence assessment determined by closed-field fluorescence imaging of fresh resected margins
accurately predicted the presence of disease in 33/39 positive margins yielding an overall sensitivity of 85%,
specificity of 95%, positive predictive value (PPV) of 94%, and a negative predictive value (NPV) of 87%,
which was superior to both surgical assessment (54%, 61%, 57%, and 58%) and pathological assessment
(49%, 95%, 91%, and 66%), respectively. When the power of the technique was evaluated using human-
derived tumour tissues, as little as 0.5mg (1mm3) of tumour tissue was identified (tumour-to-background-
ratio:5.2). When the sensitivity/specificity of fluorescence-guided pathology was determined using traditional
histological assessment as the gold standard in human tissues obtained during fluorescence-guided surgery,
the technique was highly accurate with a sensitivity of 91%, specificity of 85%, PPV of 81%, and NPV of
93% for 90 human-derived samples. This approach can be used as a companion to the pathologist, eliminat-
ing confounding factors while impacting surgical intervention and patient management.
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Introduction
Currently, surgeons and pathologists lack the
adequate and reliable intraoperative tools to consis-
tently discriminate tumour and normal tissue in real-
time. This has resulted in high rates of positive or
close margins in head and neck squamous cell
carcinoma (HNSCC), which is associated with high
local rates of recurrence [1]. Positive margins are
associated with a 22% local recurrence rate, com-
pared to 3.9% local recurrences in patients with
tumour-free margins [2]. Moreover, involved surgical
margins increase the risk of death at 5 years by 90%,
indicating that surgical margin status remains a pri-
mary predictor for survival and local recurrence [3].
Nevertheless, in current clinical practice, tumour pos-
itive margins are found in up to 40% of patients on
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histopathological review [4,5], for which there is
clear need for improvement.
Currently, intraoperative frozen section analysis of
margins is a widely used tool to assist the surgeon in
achieving complete tumour resection. While this
methodology permits rapid turnaround for diagnosis
of freshly resected tissue, the process is not real-time
and there is a poor correlation of frozen and perma-
nent margin status in HNSCC. In a recent study, dis-
cordance between frozen and permanent margins was
identified in 20% of cases [6]. More specifically, the
false-negative rate for poorly differentiated carci-
noma, lymphovascular invasion, and perivascular
invasion was 14%, 36%, and 26%, respectively. In
addition to misinterpretation and specimen under-
sampling, these histopathological features are associ-
ated with a higher rate of discrepancy between frozen
and permanent assessment [7–9]. Considering
HNSCC has the highest rate of intraoperative consul-
tations [10], investigating alternative more accurate
methodologies for margin assessment is of greatest
relevance to this tumour type. However, discordant
final diagnosis affects patient management in all
tumour types, both at the surgical intervention and
long-term treatment stages.
In response to limited improvement of survival rates
in surgical oncology, there have been several landmark
clinical trials demonstrating that cancer can be accu-
rately identified in real-time using fluorescence-guided
surgical techniques [11–13]. As a result, the field of
fluorescence-guided surgery has grown significantly
and additional clinical trials are underway to evaluate a
range of fluorescently labeled, cancer-specific contrast
agents to guide surgical ablation in multiple cancer
types. The advantage of fluorescence-guided surgery is
that it localizes diseased tissue that would otherwise
remain undetected during traditional standard of care.
For example, in phase III clinical trials, oral adminis-
tration of 5-aminolevulinic acid (5-ALA) was shown to
improve progression-free survival [12,14]. Recently,
our group conducted a phase I dose-escalation study in
twelve patients using cetuximab-IRDye800CW in squa-
mous cell carcinoma arising in the head and neck
(clinicaltrials.gov identifier: NCT01987375). During
the intraoperative imaging, disease-specific fluores-
cence generated high levels of contrast (tumour-to-
background ratios average of 5.2) to delineate cancer
from normal tissues in the operative field [11,15]. Dur-
ing this clinical trial, it became apparent that identifica-
tion of disease by fluorescence imaging of the surgical
specimen had significant advantages for the patholo-
gist, such as identifying areas in the gross specimen
where the margins are likely to be close or positive,
thus allowing efficient and focused tumour sampling
for histological sections. Considering the challenges of
appropriate sampling and time required for intraopera-
tive consultation, we hypothesize that a cancer-specific
fluorescent contrast agent, systemically injected prior
to the surgical procedure, could be used to guide path-
ological assessment of close or positive margins. Imag-
ing the primary specimen in the frozen section room
prior to sampling the tumour periphery may help guide
the pathologist to identify suspicious areas for frozen
section, which, if positive for carcinoma, would allow
the surgeon to re-excise this area at the time of the
original procedure. As a proof of concept, we set up a
translational experimental approach in which we eval-
uated the technique in a preclinical model of cancer
where bioluminescence imaging was utilized as the
gold standard for detection of microscopic disease. To
evaluate clinical feasibility of this fluorescence-guided
pathology approach, we evaluated HNSCC tumour
specimens resected from animals and humans after sys-
temic injection of cetuximab-IRDye800CW. To deter-
mine the sensitivity and specificity of fluorescence-
guided pathology, we compared the approach to tradi-
tional histological assessment using human tissues




Conjugation of cetuximab to IRDye800CW (excita-
tion: 778 nm, emission: 798 nm) was performed
under cGMP conditions as previously reported [16].
Briefly, cetuximabVR (ImClone LLC, subsidiary of Eli
Lilly and Company, Branchburg, NJ) was concen-
trated and pH adjusted by buffer exchange to a
10 mg/ml solution in 50 mM potassium phosphate,
pH 8.5. IRDye800CW NHS ester (LI-COR Bioscien-
ces, Lincoln, NE) was conjugated to cetuximab for 2
hrs at 208C in the dark, at a molar ratio of 2.3:1.
After column filtration to remove unconjugated dye
and exchange buffer to phosphate buffered saline
(PBS), pH 7, the final protein concentration adjusted
to 2 mg/ml, the product was sterilized by filtration
and placed into single use vials and stored at 48C
until used.
Cell line and animal models
The human head and neck squamous cell carcinoma
cell line SCC1 was obtained from the University of
Michigan and maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) with 10% fetal bovine
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serum and 2.6 mM L-glutamine. Cells were cultured
at 378C and 5% CO2, passaged at 70 to 90% conflu-
ence, and harvested with 0.05% trypsin/0.53 mM
EDTA. Cell lines were genetically modified with a
luciferase-expressing construct (pCMV pGL3 Lucif-
erase, Addgene, Cambridge, MA). Athymic female
nude mice (aged 6–8 weeks) were obtained from
Frederick Cancer Research (Frederick, MD). For sub-
cutaneous inoculation, 2 3 106 SCC1-luc cells were
bilaterally implanted in the right and left hind flank
of each mouse. Institutional Animal Care and Use
Committee (IACUC) at the University of Alabama at
Birmingham approved all animal protocols (APN
130908793; 140310064).
In vivo margin study
Three weeks post implant (average tumour size:
188.36 15 mm3), athymic nude mice (n5 10) bear-
ing bilateral subcutaneous flank tumours received
225 lg (62.5 mg/m2, one-quarter cetuximab therapeu-
tic dose) of cetuximab-IRDye800CW (excitation:
778 nm, emission: 798 nm) intravenously via tail
vein. Five days post injection, mice were sacrificed,
tumours resected and four margins (1 cm 3 0.5 cm
3 0.5 cm, each) collected from each wound bed (80
margins total). For the surgeon’s assessment, an oto-
laryngology surgery resident (EMW) visually
assessed the resected margins to determine the pres-
ence of tumour. Fluorescence imaging of each mar-
gin was performed using the Pearl Impulse (LI-COR
Biosciences, Lincoln, NE). For the imaging, speci-
mens were placed in the imaging tray and acquisi-
tions were performed using onboard instrument
software at the 800 nm channel (emission filter 810–
830 nm), 85 lm resolution, and 0 focus position. Flu-
orescence imaging was performed on both sides of
each specimen. After addition of a luciferase assay
agent (E1500, Promega, Madison, WI) biolumines-
cence imaging (BLI, IVIS-100, Caliper Life Sciences,
Waltham, MA) was performed on each resected mar-
gin using the 500–570 nm emission filter setting. The
term bioluminescence describes the emission of light
generated as a byproduct of the enzymatic reaction
between firefly luciferase enzyme and a substrate,
luciferin. Margins were fixed in formalin and proc-
essed into paraffin blocks; 5 mm tissue sections were
then cut (2) 100 lm apart, placed on glass slides, and
stained with haematoxylin & eosin (H&E). A Univer-
sity of Alabama at Birmingham (UAB) board-
certified pathologist (TMS) was blinded to the biolu-
minescence data and fluorescence grading and exam-
ined the slides by light microscopy and H&E
staining to determine if tumour cells were present or
absent in the margins by conventional analysis. The
blinded fluorescence assessment was performed using
onboard instrument software (ImageStudio, LI-COR
Biosciences). For the assessment, the threshold was
uniquely adjusted for each sample to reveal heteroge-
neity in fluorescence intensity within each sample, as
previously described [17–19]. Areas of high signal
relative to the surrounding tissue were considered
positive. Margins were given a binary assignment
(6) determined by the presence or absence of tumour
by each test. The diagnostic accuracy of the sur-
geon’s assessment, fluorescence prediction, and con-
ventional histological evaluation using H&E stain
was compared to the bioluminescence (gold standard)
results to calculate the sensitivity, specificity, positive
predictive value (PPV), and negative predictive value
(NPV).
In vitro margin study
To produce surrogate margins using a xenograft
mouse model, athymic nude mice (n5 5) bearing
subcutaneous flank tumours (SCC1) received 225 lg
(62.5 mg/m2, one-quarter cetuximab therapeutic
dose) of cetuximab-IRDye800CW intravenously via
tail vein. Five days post injection, mice were sacri-
ficed, tumours resected, grossly sectioned and
weighed. Muscle (2 cm 3 1 cm 3 0.5 cm) was
excised from the contralateral flank to serve as nor-
mal tissue. Serially sectioned tumour fragments rang-
ing from 5 mg to 0.5 mg in size were then placed
onto the excised muscle bed and imaged using the
Pearl Impulse. For evaluation using clinically
obtained tissue, human tissue obtained during a clini-
cal trial evaluating the safety of cetuximab-
IRDye800CW in patients undergoing surgical inter-
vention for squamous cell carcinoma arising in the
head and neck (clinicaltrials.gov identi-
fier#NCT01987375) were examined. Three to 4 days
prior to surgery, patients received intravenous infu-
sion of 62.5 mg/m2 cetuximab-IRDye800CW.
Tumour tissue excised from the bulk tumour by the
ablative surgeon was serially sectioned and weighed
to produce sections ranging from 5 mg to 0.5 mg.
These sections were then placed on patient-matched
muscle and imaged using the Pearl Impulse.
Informed consent was obtained from participating
patients and the UAB Institutional Review Board pre-
viously approved the research.
Surrogate margin study
During a clinical trial evaluating the safety of
cetuximab-IRDye800CW in patients undergoing
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surgical intervention for squamous cell carcinoma
arising in the head and neck (clinicaltrials.gov identi-
fier#NCT01987375), a total of 45 punch biopsies
(1 cm 3 4 mm) were collected by the ablative sur-
geon from resected primary tumour specimens
excised from three patients (n5 15 each). Biopsies
were then bisected to produce 90 tissue samples,
imaged with Pearl Impulse, and histologically proc-
essed. After H&E staining, UAB pathologists exam-
ined the slides by light microscopy to determine if
tumour cells were present or absent in the margins
by conventional analysis. Each specimen was subdi-
vided into quarters and a binary assignment given to
each quarter based on the presence or absence of
cancer by histological analysis and fluorescence
assessment. The result of fluorescence prediction
using fluorescence imaging was compared to conven-
tional histological evaluation using H&E staining
(gold standard) to calculate the sensitivity, specific-
ity, PPV, and NPV. Informed consent was obtained
from participating patients and the UAB Institutional
Review Board previously approved the research.
Fluorescence microscopy
Unstained slide-mounted sections of patient-derived
tissues were imaged (4003) using a fluorescence
microscope (Leica DMI6000B) equipped with a
DFC365FX near-infrared camera and an XCite200
light source and onboard LAS X software. After
Figure 1. Fluorescence localization of disease is compared to histopathological assessment and surgeon assessment using luciferase
imaging as gold standard. (A) Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) are shown
for surgeon, pathologist, and fluorescence assessment of tumour wound-bed margins compared to bioluminescence, which served as
the gold standard. Representative images are shown of the margins assessed for (B) bioluminescence, (C) haematoxylin and eosin
staining, and (D) matching fluorescence acquisition.
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fluorescence acquisition, slides were H&E stained
and matching brightfield images (4003) were
acquired using an Olympus IX70 equipped with a
DP72, 12.8 megapixel cooled digital colour camera.
Results
Fluorescence assessment accurately predicts the
presence of residual disease in an animal model
of surgical margins
To evaluate the feasibility of fluorescence-guided
pathology to detect subclinical disease, an animal
model of diseased margins was used to compare fluo-
rescence assessment to conventional assessment using
bioluminescence, in lieu of histology as the gold
standard. For the experiment, 80 margins were col-
lected from post-resection wound beds of 20 lucifer-
ase positive SCC1-luc tumours resected from the
subcutaneous flank of mice that received a systemic
administration of cetuximab-IRDye800CW. As
shown in Figure 1A, the fluorescence assessment
determined by closed-field fluorescence imaging
(Pearl) of fresh resected margins accurately predicted
the presence of disease in 33 of 39 positive margins
yielding an overall sensitivity of 85%, specificity of
95%, PPV of 94%, and NPV of 87%. More impor-
tantly, fluorescence successfully predicted the
absence of disease in 39 out of 41 negative margins,
as determined by bioluminescence imaging. For the
histological assessment, all 80 tissue margins were
sectioned (5 lm full-face thickness), slide-mounted
for H&E staining (two per margin, cut 100 lm apart)
and then examined by a board-certified pathologist
and a binary (6) value was assigned for each margin
based on the presence of tumour. During the assess-
ment, the pathologist accurately predicted the pres-
ence of tumour in 21 out of 39 disease containing
margins (TMS) yielding an overall sensitivity of
49%, specificity of 95%, PPV of 91%, and a NPV of
66%. However, similarly to the fluorescence assess-
ment group, the pathologist correctly predicted the
absence of disease in 39 out of 41 negative margins.
The surgeon assessment was also evaluated and
found to have a sensitivity of 54%, specificity of
61%, PPV of 57%, and NPV of 58%. To demonstrate
the disease localization between the various modal-
ities evaluated, a bioluminescence image (Figure 1B),
matching H&E stained histological section (Figure
1C), and fluorescence acquisition (Figure 1D) of a
representative margin containing residual disease are
shown.
Subclinical residual tumour was successfully
localized using fluorescence imaging in a model
of positive surgical margins using mouse tissues
To evaluate the potential of fluorescence-guided
pathology to localize subclinical tumour during mar-
gin assessment, human xenograft tumours were
grown subcutaneously in mice that received a sys-
temic injection of cetuximab-IRDye800CW. Tumours
were resected (day 5 post cetuximab-IRDye800CW
injection) and serially sectioned to produce 5 mg, 1
mg, and 0.5 mg pieces of tumour. To create surrogate
margins of residual disease, muscle, skin, and adi-
pose tissue were excised and used as normal tissue
backgrounds. The ability to discern between tumour
and normal tissue was quantified using tumour-to-
Figure 2. Minimum disease detectable in mouse tissues. Representative fluorescence and brightfield images are shown for 5 mg,
1 mg, and 0.5 mg tumour fragments on a bed of muscle, skin, or adipose tissue from mice infused with cetuximab-IRDye800CW 5
days prior to tumour resection. Inset values represent tumour to background ratios for the respective tissue.
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background ratios (TBR) of mean fluorescence inten-
sity. When each tumour tissue fragment was serially
placed on a respective background tissue, the tumour
was successfully fluorescently localized (Figure 2)
with TBRs ranging between 14.4 for the muscle
background and 9.8 for the skin background using
the 5 mg tumour fragment. When evaluating the sen-
sitivity of the approach to detect subclinical disease
using the 0.5 mg tumour fragment, TBR values
ranged from 4.7 to 2.3 when adipose and muscle tis-
sue, respectively, were tested.
Assessment of subclinical disease using
fluorescence imaging in a model of positive
surgical margins using human tissues
To demonstrate the translatability of the
fluorescence-guided pathology approach, resected
tumour tissue (squamous cell carcinoma) from a clin-
ical trial patient, who received cetuximab-
IRDye800CW (62.5 mg/m2 dose) 3 days prior to
undergoing a total glossectomy, was serially sec-
tioned to produce 5 mg, 1 mg, and 0.5 mg tumour
fragments. Patient-matched tissues (muscle, skin, and
adipose) were used as background and individual
tumour fragments were serially placed on each back-
ground tissue type to mimic surgical margins. As
shown in Figure 3, the human tumour fragments
were successfully visualized (TBR> 1) at each
tumour fragment weight and tissue background. For
the 5 mg fragment, TBRs ranged between 9.2 for the
muscle background and 3.7 for the skin background.
Likewise, the subclinical 0.5 mg fragment (1 mm3)
exhibited TBR values ranging between 5.2 for the
muscle background and 2.5 for the skin background.
Matching brightfield images are also shown to dem-
onstrate the difficulty in localizing the subclinical
diseased tissue under white light conditions.
Fluorescence-guided pathology is highly sensitive
when compared to traditional histological
methods
To compare the reliability of fluorescence-guided
pathology to the current standard of care, 4 mm
tissue punch biopsies (n5 45) collected from
resected primary tumour specimens (n5 3, Figure
4A, B) from patients who received cetuximab-
IRDye800CW (62.5 mg/m2 dose) 3 days prior to
undergoing ablative surgery were bisected and
imaged with the closed-field fluorescence imaging
device prior to formalin fixation and paraffin
embedding. Images obtained of the whole tissue
samples were subdivided into quarters and a bina-
ry6 assessment was assigned to each quarter
based on the presence of disease as determined by
fluorescence assessment (Figure 4C). The samples
were then processed for histology and the histo-
logical assessment of each biopsy quarter was per-
formed using H&E stained sections of each punch
biopsy by a board-certified pathologist in a
blinded fashion (Figure 4D). Biopsies were
bisected to reduce potential sample error during
the histological processing. A fluorescence image
of a representative primary specimen annotated
with the locations of punch biopsy samples is
shown in Figure 4B. Using histological assessment
as the gold standard, fluorescence assessment
Figure 3. Minimum disease detectable in human tissues. Representative fluorescence and brightfield images are shown for 5 mg,
1 mg, and 0.5 mg human-derived tumour fragments on a bed of patient-matched muscle, skin, or adipose tissue from a patient
infused with cetuximab-IRDye800CW 3 days prior to tumour resection. Inset values represent tumour to background ratios for the
respective tissue.
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accurately predicted the presence of disease in 137
out of 151 tumour-containing quarters to yield an
overall sensitivity of 91%, specificity of 85%,
PPV of 81%, and NPV of 93% for 90 punch
biopsy samples and 360 quarters.
Fluorescence microscopy confirmed disease-
specific fluorescence intensity
To confirm the disease-specific nature of the fluores-
cence intensity observed in the human tissues tested,
fluorescence microscopy was performed. Figure 5A
shows an H&E stained section of a primary tumour
specimen of oral (tongue) squamous cell carcinoma
from a patient who received cetuximab-
IRDye800CW (62.5 mg/m2 dose) 3 days prior to
undergoing ablative surgery. A board-certified pathol-
ogist annotated the image (green line) to outline the
cancer-containing areas, which correlated precisely
with the fluorescence microscopy image shown in
Figure 5B. A nuclear stain image (DAPI) is also
shown in Figure 5C.
Discussion
In this proof-of-principle study, we evaluated the
potential of disease-specific fluorescence to positively
identify subclinical tumour within the post-resection
wound bed and within surgical margins. To recreate
surgical margins for testing, surrogate margins were
generated using a translational experimental design
with both mouse and human tissue. The ability of
fluorescence assessment to localize disease in these
margins was shown to be highly sensitive and spe-
cific with a NPV of 87%, which was superior to both
surgical assessment (58%) and pathological assess-
ment (66%), when using bioluminescence imaging as
Figure 4. Fluorescence assessment of patient-derived surrogate margins. Fluorescence (A) and brightfield (B) images are shown of
representative resected primary tumour specimens from a patient who received cetuximab-IRDye800CW 3 days prior to undergoing
ablative surgery. Areas sampled with 4 mm punch biopsy are annotated with histological assessment (6). Specimens were subdivided
into quarters and a binary6 assessment was assigned to each quarter based on the presence of disease as determined independently
by (C) fluorescence assessment of whole tissue and (D) histological assessment of slide-mounted, H&E-stained sections. Using histo-
logical assessment as the gold standard, results from fluorescence assessment were correlated with the gold standard to determine
sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
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the gold standard. Using both mouse and human tis-
sues, we found that as little as 0.5 mg of human
tumour tissue was identified (TBR: 5.2) when
patient-matched muscle was used as background. In
the clinical setting, a 0.5 mg tumour is equivalent to
less than 105 cells with a tumour diameter of 1 mm
[20]. This would be considered subclinical disease,
since it is smaller than is currently detectable. When
the fluorescence-guided pathology technique was
used to assess subclinical disease fragments (surro-
gate margins) collected from primary tumour speci-
mens from patients who received cetuximab-
IRDye800CW prior to undergoing ablative surgery,
the approach was shown to be highly effective to
localize cancer-containing quarters with a NPV of
93%. Importantly, fluorescence microscopy of the
surrogate margins demonstrated the cancer-specific
nature of the fluorescence, which confirmed that the
fluorescence signal correlated with tumour-containing
areas.
Although the limit of fluorescence detection was
found to be approximately 0.5 mg of tumour, it far
exceeded current detection modalities. The fluores-
cence assessment (sensitivity: 85%) strongly outper-
formed the surgeon (sensitivity: 54%) and the
pathologist (sensitivity: 49%) at identifying positive
margins (Figure 1). There is a possibility that sam-
pling error during tissue block sectioning (unsec-
tioned tumour present deeper in the tissue block)
played a role in the low sensitivity of the pathology
assessment. However, when the ability of pathologi-
cal assessment to correctly identify negative margins
was evaluated, fluorescence assessment (specificity:
95%) and pathology assessment performed identi-
cally, while the surgeon assessment remained low
(specificity: 61%). This comparison illustrates the
success of pathological assessment when tumour-
containing tissue is captured on the slide for analysis.
However, if sampling error occurs and the tumour
region is not identified for sectioning, the margin
will be erroneously assessed as negative. Using fluo-
rescence assessment, the pathologist or surgeon is
able to perform directed or fluorescent-guided sam-
pling which may limit the false negative result from
sampling error, particularly in larger specimens. For
example, if initial levels from a tissue block contain-
ing a tissue section from a fluorescently “hot” area
are negative for tumour, the pathologist would be
prompted to obtain deeper levels from this block
where tumour is likely hiding, thereby turning a
potentially false negative margin into a true positive
margin. This underlines the benefit of fluorescence to
localize suspicious areas of the margin for more
accurate histopathological assessment.
For exogenously administered fluorescence imaging
agents, target-specific differences within tissues may
limit the widespread application of fluorescence-guided
pathology. During the study, epidermal growth factor
receptor (EGFR), which served as the targeted epitope
of cetuximab-IRDye800CW, in the skin led to a 50%
reduction in TBRs when patient-matched skin was
used as the background. Likewise, restraints in fluores-
cence penetration may limit the application when
larger margins (>1 cm) are assessed. Lower wave-
length dyes are limited in sensitivity due to the high
attenuation and scattering effects that are associated
with these dyes. For the current study, the near infrared
IRDye800CW was utilized due to the superior penetra-
tion (1 cm) provided by this dye [21]. As the
fluorescence-guided pathology approach is developed,
it will be critical for the pathologist to be aware of the
off-target accumulation and the fluorescence potential
of the imaging agent.
This report provides evidence that tumour-specific
fluorescence can be used by the surgeon or patholo-
gist to guide sampling for frozen sections, but does
not replace the need for histological diagnosis.
Although fluorescence guidance may be better than
Figure 5. Fluorescence microscopy of cetuximab-IRDye800CW infused patient-derived tumour. (A) Representative H&E microscopy
image (4003) with pathology-positive areas of tumour outlined in green. (B) Fluorescence microscopy (4003) acquired using custom
IRDye800CW filter sets is shown with correlating (C) DAPI nuclear stain.
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conventional sampling techniques, which include
inspection and palpation, it does not allow for histo-
pathological analysis of tissue to confirm margins on
frozen sections. With the substantial increase in clini-
cal trials evaluating fluorescence-guided surgery, it is
not difficult to imagine the future of surgical oncol-
ogy incorporating such technology. These tools serve
to enhance the surgeon’s ability to successfully iden-
tify and resect tumour while eliminating over-
resection to retain normal function. Fluorescence-
guided pathology can then be easily implemented
into the clinical care workflow and used in adjunct to
fluorescence-guided surgery to help guide the pathol-
ogist when assessing margins for both intraoperative
assessment and staging.
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